Monastrol (100 μM, HY101071A, MCE) was added to M2 medium of MII oocytes for 1.5 h for chromosome spreading. Reversine (100 nM, HY-14711, MCE) was added to oocytes starting from NEBD to inhibit SAC activity. ZM447439 (10 μM, HY-10128, MCE) or AZD1152 (500 nM, SML0268, Sigma-Aldrich) was used to treat oocytes for 15 min or 30 min at 5 h after NEBD to inhibit AURKB/C. S-Trityl-L-cystein (STLC) (0.75 μM, 164739, Sigma-Aldrich) was used to treat oocytes at 5 h after NEBD to inhibit KIF11.
Sml0268
Manufactured by Merck Group
Sourced in United Kingdom
The SML0268 is a laboratory equipment product manufactured by Merck Group. It serves as a general-purpose device for various laboratory applications. The core function of the SML0268 is to provide a controlled and regulated environment for various scientific experiments and analyses. However, a more detailed description while maintaining an unbiased and factual approach is not available.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using sml0268
1
Chromosome Spreading and Spindle Inhibition
2
Compound Concentration Optimization for Cell Lines
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The final concentrations used for the compound were as follows. For HDFs and H1299 cells, Aurora kinase inhibitor II, 8 μM (CAS# 331770-21-9; 189404; Merck); Cdk2 inhibitor IV, NU6140, 4 μM (CAS# 444723-13-1; 238804; Merck); PDGFR tyrosine kinase inhibitor V, 8 μM (CAS# 347155-76-4; 521234; Merck); Rho kinase inhibitor IV, 10 μM (555554, Merck; or CAS# 913844-45-8; 2485, Tocris, Bristol, UK); SU6656, 10 μM (CAS# 330161-87-0; 572635; Merck); ZM1 (ZM-447439), 2 μM (CAS# 331771-20-1; sc-200696, Santa Cruz Biotechnology); EGFR inhibitor, 0.5 μM (CAS# 879127-07-8; 324674; Merck); JNK inhibitor IX, 0.5 μM (CAS# 312917-14-9; 420136, Merck); MK2a inhibitor, 0.7 μM (CAS# 41179-33-3; 475863, Merck); and AZD1152-HQPA, 0.5 μM (CAS# 722544-51-6; SML0268, Sigma-Aldrich). For HeLa cells, Rho kinase inhibitor IV, Cdk2 inhibitor IV, and ZM1 were used at concentrations of 1.5, 4, and 1.5 μM, respectively. Nocodazole, 200 ng/ml (CAS# 31430-18-9; 487928; Merck); paclitaxel, 10 μM (CAS# 33069-62-4; T7402; Sigma-Aldrich).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!